The Top Five Product Searches on CPHI Online: January
Which were the products that drew the most interest in the CPHI directory in January? We analyse search data from the CPHI directory…
1. Bedrolite – THC <1.0%/CBD 9% - Bedrocan
This CBD-only based product from natural API medicinal cannabis supplier Bedrocan roared straight into the top five in January to become the most searched on CPHI Online during the month.
Available in granular form, it is typically used by patients with severe, intractable forms of epilepsy. The virtual absence of THC means it does not have psychoactive properties.
2. Avoquin 4% - Avalon Pharma
This skin lightening cream finally lost its top spot this month, slipping down one place in the pecking order, but still attracting a huge amount of interest on CPHI Online.
The formulation – sold in African, Middle Eastern and Asian markets -- contains hydroquinone, which the company describes as the ‘gold standard’ for treatment of skin hyperpigmentation and claims has been proven in clinical trials to be the safest and most effective skin lightening agent.
Skin lightening refers to the practice of using chemical substances to lighten the skin or provide an even skin colour by reducing the melanin concentration. Hydroquinone is currently not approved for this purpose in Europe.
3. Avocom-M cream – Avalon Pharma
This anti-inflammatory, antipruritic and anti-allergic cream, also from Avalon Pharma, slipped one place in January. The product is a unique combination of corticosteroid, Mometasone Furoate, (0.1% concentration) and anti-fungal Miconazole Nitrate (2%).
4. Avalon Avotin -Avalon Pharma
Despite this product also slipping one place, Saudi Arabia’s Avalon retains its record of having three products occupying top five positions. This formulation of Tretinoin cream, a derivative of vitamin A, was a new entry in December. It is a versatile retinoid that works by increasing the growth rate of skin cells and is used to treat a variety of skin conditions, from acne to aging.
5. Trofocard & Trofocard Max - Uni-Pharma
Uni-Pharma’s Spasmo-Apotel fell out of the top five in January, but the Greek company managed to replace it with one of their other products. Trofocard is a dietary supplement for magnesium deficiency and is available in gastro-resistant tablets, injectable solution and film-coated tablets.
Related News
-
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News CPHI Milan Speaker Spotlight: CDMO relations with Pharma and Start-Ups
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News Women in Pharma: Advocating for trans healthcare in pharma
In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance